giant cell arteritis

News

Novartis hopes of bringing Cosentyx to patients with giant cell arteritis seem to be over after the drug missed all the endpoints in a phase 3 trial.

News

AbbVie has picked up another indication for its JAK inhibitor Rinvoq in the EU, becoming the first approved oral therapy for giant cell arteritis.

News

AbbVie's Rinvoq is poised to become the first oral targeted treatment for giant cell arteritis in the EU after being backed by the CHMP.

News

Regulator grants six-month review.

News

Drug successful in late stage trial for giant cell arteritis